Singapore Medical Device Classification: Class A, B, C and D Explained
A practical guide to Singapore medical device risk classification and how Class A, B, C and D affect HSA registration, evidence expectations and market-entry strategy.
8/21/20263 min read
Medical device classification is one of the most important early decisions in a Singapore market-entry project. It determines whether registration is required, which HSA evaluation route may apply, how much evidence is expected and how the company should plan its launch timeline.
Singapore classifies medical devices into four risk classes: Class A, B, C and D. Class A is the lowest risk class, while Class D is the highest. This risk-based approach allows lower-risk products to face lighter controls while higher-risk products receive more detailed regulatory review.
Why classification matters commercially
Classification is not only a regulatory label. It affects budget, timing, distributor planning and the amount of technical documentation needed before supply. A Class A product may be exempt from product registration, although dealer licensing and other obligations may still apply. Class B, C and D products generally require registration with HSA before supply in Singapore.
For overseas manufacturers, the classification decision should be made before appointing local partners or promising launch dates. If the device is later classified higher than expected, the registration route, fees, review timeline and evidence package can change materially.
What HSA considers when classifying a device
HSA considers the intended purpose of the product, how it operates, the user, the patient population and the type of technology involved. Factors such as invasiveness, duration of contact, whether the device is active, whether it delivers energy or substances, and whether it supports diagnosis or treatment can all affect classification.
This is why two products that look similar commercially may fall into different risk classes. A simple accessory, a monitoring device and software that supports clinical decision-making may all raise different regulatory questions.
Class A: low-risk devices
Class A medical devices are generally low-risk products. Examples may include simple non-invasive devices or products with limited clinical risk when used as intended. Class A devices are typically exempt from product registration in Singapore, but companies should not treat exemption as absence of regulation.
Dealers still need to consider licensing, record keeping, product claims and post-market responsibilities. If the product is imported or supplied by a local company, the relevant dealer obligations should be checked before commercial launch.
Class B: low-to-moderate risk devices
Class B products usually require registration with HSA before supply. These devices present more risk than Class A devices but are not in the higher-risk categories. Many diagnostic, monitoring and active devices may fall here depending on their intended use and design.
For Class B devices, the registration route may be more efficient if the product already has recognised overseas approvals and the Singapore intended use aligns with those approvals. Still, the submission must be internally consistent. Labelling, model lists, certificates and technical documentation should all tell the same regulatory story.
Class C and D: higher-risk devices
Class C and D devices require more careful planning because they carry higher clinical risk. Class C devices may include products where failure or misuse could lead to serious deterioration in health. Class D devices represent the highest-risk category and may involve life-supporting, life-sustaining or other high-consequence uses.
For these devices, companies should expect deeper review of clinical evidence, risk management, quality systems, manufacturing controls and post-market arrangements. The market-entry plan should allow enough time for HSA questions and internal response preparation.
Software and digital health products
Classification can be especially nuanced for software, Software as a Medical Device (SaMD) and clinical decision support tools. The key issue is not simply whether the product is digital, but what it does and how its output is used. Software that merely stores or displays information may be treated differently from software that analyses patient data or supports diagnosis or treatment decisions.
Companies should review the intended claims, user workflow and clinical significance of the software output. Overly broad marketing claims can unintentionally push a product into a higher-risk regulatory position.
Common classification mistakes
One common mistake is relying only on classification in another market. Overseas classification can be useful context, but Singapore classification should still be assessed under HSA rules. Another mistake is classifying based on the product category name rather than intended purpose. A device accessory, for example, may need to be assessed in relation to the device it supports and the role it plays.
A third mistake is treating classification as something to confirm after commercial planning. In reality, classification should guide commercial planning. It informs who needs to be involved, what documents should be prepared and when a realistic launch date can be set.
Practical takeaway
A good classification assessment gives the company more than a risk class. It gives the company a regulatory roadmap. It clarifies whether registration is required, which pathway may be available, what evidence is needed and how much post-market control should be expected.
For medical device companies entering Singapore, classification should be treated as an early strategic decision. Getting it right helps avoid rework, protects launch timelines and creates a stronger foundation for HSA registration and long-term compliance.
References: Health Sciences Authority (HSA), Singapore - medical device regulatory overview, risk classification guidance, registration guidance, digital health and SaMD guidance, and fees and turnaround time guidance.
✉️ Email Address:
📍Singapore Headquarters:
14, Robinson Road, #08-01A
Far East Finance Building
Singapore 048545
📍United Kingdom Office:
71–75 Shelton Street
London, WC2H 9JQ
United Kingdom